Drugs / SSGJ-709
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07016490 | Jun 2025 → Sep 2027 expected | cancer | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSGJ-709 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07016490 ↗ |
| Route | Intravenous | “Dose Escalation Level includes 5 levels, Q3W IV.” NCT07016490 ↗ |